Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.68 -0.5%	$9.92	$3.47 ▼ $12.43	$1.77B	1.83	1.63 million shs	777,814 shs
APGE Apogee Therapeutics	$36.52 -6.9%	$40.38	$26.20 ▼ $63.50	$1.68B	1.47	592,793 shs	1.82 million shs
IDRA Idera Pharmaceuticals		$0.50	$0.22 ▼ $8.67	$450.52M	1.25	464,030 shs	21,870 shs
IMCR Immunocore	$33.17 +2.3%	$32.37	$23.15 ▼ $41.54	$1.67B	0.77	345,317 shs	103,269 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-1.97%	+0.77%	+16.35%	+53.26%	+231.64%
APGE Apogee Therapeutics	-17.48%	-9.65%	-4.25%	+36.30%	+3.21%
IDRA Idera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
IMCR Immunocore	-1.82%	+3.28%	-12.99%	+32.12%	-12.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.4272 of 5 stars	1.4	3.0	0.0	4.2	3.1	2.5	0.6
APGE Apogee Therapeutics	2.9252 of 5 stars	3.5	2.0	0.0	0.0	2.5	4.2	0.0
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	2.7203 of 5 stars	4.3	0.0	0.0	0.0	3.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-9.49% Downside
APGE Apogee Therapeutics	3.00	Buy	$99.00	171.08% Upside
IDRA Idera Pharmaceuticals	0.00	N/A	N/A	N/A
IMCR Immunocore	2.55	Moderate Buy	$58.89	77.54% Upside

Current Analyst Ratings Breakdown

Latest IDRA, APGE, IMCR, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$100.00 ➝ $115.00
7/2/2025	APGE Apogee Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/2/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
5/27/2025	IMCR Immunocore	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
5/8/2025	IMCR Immunocore	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$85.00 ➝ $86.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	9.92	N/A	N/A	$1.37 per share	8.53
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	0.29	$0.56 per share	N/A
IMCR Immunocore	$310.20M	5.37	N/A	N/A	$7.20 per share	4.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
APGE Apogee Therapeutics	-$182.15M	-$3.60	N/A	N/A	N/A	N/A	-28.35%	-26.98%	8/11/2025 (Estimated)
IDRA Idera Pharmaceuticals	$98.09M	-$0.32	N/A	N/A	N/A	N/A	-68.74%	-34.26%	N/A
IMCR Immunocore	-$51.09M	-$0.43	N/A	N/A	N/A	-6.48%	-5.86%	-2.09%	8/6/2025 (Estimated)

Latest IDRA, APGE, IMCR, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	APGE Apogee Therapeutics	-$1.19	-$0.95	+$0.24	-$0.95	N/A	N/A
5/7/2025	Q1 2025	IMCR Immunocore	-$0.35	$0.10	+$0.45	$0.10	$108.82 million	$125.13 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
APGE Apogee Therapeutics	N/A	15.82	15.82
IDRA Idera Pharmaceuticals	N/A	1.56	1.56
IMCR Immunocore	1.03	6.36	6.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
APGE Apogee Therapeutics	79.04%
IDRA Idera Pharmaceuticals	12.18%
IMCR Immunocore	84.50%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
APGE Apogee Therapeutics	42.77%
IDRA Idera Pharmaceuticals	5.05%
IMCR Immunocore	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
APGE Apogee Therapeutics	91	46.05 million	26.35 million	Optionable
IDRA Idera Pharmaceuticals	32	62.36 million	59.21 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable

IDRA, APGE, IMCR, and ADPT Headlines

Recent News About These Companies

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

July 2, 2025 | zacks.com

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

June 30, 2025 | finance.yahoo.com

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

June 30, 2025 | globenewswire.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from Analysts

June 29, 2025 | americanbankingnews.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Analysts

June 29, 2025 | marketbeat.com

IMCR - Immunocore Holdings PLC ADR Ownership | Morningstar

June 28, 2025 | morningstar.comM

IMCR Immunocore Holdings plc - Seeking Alpha

June 26, 2025 | seekingalpha.com

Notable Two Hundred Day Moving Average Cross - IMCR

June 24, 2025 | nasdaq.com

Immunocore (NASDAQ:IMCR) Trading Down 3.4% - Here's Why

June 16, 2025 | marketbeat.com

Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges

June 15, 2025 | investing.com

Immunocore (NASDAQ:IMCR) Rating Increased to Buy at Wall Street Zen

June 14, 2025 | marketbeat.com

Cantor Fitzgerald Estimates Immunocore FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

June 10, 2025 | marketbeat.com

Immunocore (NASDAQ:IMCR) Shares Down 4.5% - What's Next?

June 9, 2025 | marketbeat.com

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

June 2, 2025 | zacks.com

Immunocore to present at the 2025 Jefferies Global Healthcare Conference

June 2, 2025 | globenewswire.com

Is it a Good Idea to Invest in Immunocore Stock Right Now?

May 23, 2025 | zacks.com

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

May 16, 2025 | zacks.com

New Strong Buy Stocks for May 8th

May 8, 2025 | zacks.com

Immunocore stock rises as Q1 results top estimates

May 7, 2025 | investing.com

Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

May 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDRA, APGE, IMCR, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.68 -0.06 (-0.51%)

As of 03:04 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Apogee Therapeutics NASDAQ:APGE

$36.52 -2.72 (-6.93%)

As of 03:04 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Idera Pharmaceuticals NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Immunocore NASDAQ:IMCR

$33.17 +0.76 (+2.34%)

As of 03:03 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time